Joseph Zakrzewski

Biography

 Joseph Zakrzewski has over 25 years of experience as an executive in the biotechnology and pharmaceutical industry, serving on the Board of Directors of publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals, Insulet Corporation, and Onxeo.  Mr. Zakrzewski also serves on the board of a number of privately held companies, is advisor to a number of entities, and is involved in a number of philanthropic activities.  He was Chairman and CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and commercialization of cardiovascular drugs based on Omega 3‘s from 2010 through 2013 successfully developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, the world’s largest healthcare-dedicated investment firm in 2010 and 2011. Prior to this, he was Chairman, President and Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines from 2007 through 2010. Xcellerex was sold to GE Healthcare. Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 through 2007. Mr. Zakrzewski had responsibility for the company’s pharmaceutical operations including R&D, business development, supply chain and manufacturing, quality, IT, and compliance. Reliant Pharmaceuticals was sold to GlaxoSmithKline in 2007. From 1988 to 2004, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company including R&D, manufacturing, finance, and business development focused on Lilly’s biotechnology and protein business. His most recent position was Vice President, Corporate Business Development, where he had global responsibility for all business development activities on a worldwide basis. A US citizen, Mr. Zakrzewski received a BS in Chemical Engineering in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.

Research Interest

pathological Diseases